Last reviewed · How we verify
20-valent Pneumococcal Conjugate Vaccine (20-valent-pneumococcal-conjugate-vaccine)
20-valent Pneumococcal Conjugate Vaccine (generic name: 20-valent-pneumococcal-conjugate-vaccine) is a Injection in the muscle or subcutaneous , 1 dose 0.5mL Vaccine drug developed by Pfizer Inc.. It is currently in preclinical development.
Injection in the muscle or subcutaneous , 1 dose 0.5mL
The 20-valent pneumococcal conjugate vaccine is used to prevent pneumococcal disease, pneumonia, and other related conditions. It has been studied in clinical trials for use in healthy Japanese infants, as well as for individuals with conditions such as chronic lymphocytic leukemia and small lymphocytic lymphoma.
-
Baseline preclinical → approval rate
+5.0pp
Industry-wide preclinical drugs reach approval ~5% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline. -
Big-pharma sponsor
+3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2036–2040 | — |
| EMA | EU | 2037–2041 | +0.7 yr |
| MHRA | GB | 2037–2041 | +0.7 yr |
| Health Canada | CA | 2037–2042 | +0.9 yr |
| TGA | AU | 2037–2042 | +1.2 yr |
| PMDA | JP | 2037–2042 | +1.5 yr |
| NMPA | CN | 2038–2043 | +2.3 yr |
| MFDS | KR | 2037–2042 | +1.4 yr |
| CDSCO | IN | 2037–2043 | +1.8 yr |
| ANVISA | BR | 2038–2043 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | 20-valent-pneumococcal-conjugate-vaccine |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Injection in the muscle or subcutaneous , 1 dose 0.5mL |
| Modality | Vaccine |
| Therapeutic area | Infectious Disease |
| Phase | preclinical |
Approved indications
Pipeline indications
- Pneumococcal Disease — preclinical
Common side effects
Key clinical trials
- A Study to Learn About How a New Pneumococcal Vaccine Works in Adults (Phase 1)
- Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With (Phase 3)
- A Study to Learn About How a New Pneumococcal Vaccine Works in Children (Phase 2)
- Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13 (Phase 3)
- A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (Phase 1)
- A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting (N/A)
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healt (Phase 3)
- Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 20-valent Pneumococcal Conjugate Vaccine CI brief — competitive landscape report
- 20-valent Pneumococcal Conjugate Vaccine updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about 20-valent Pneumococcal Conjugate Vaccine
What is 20-valent Pneumococcal Conjugate Vaccine?
How does 20-valent Pneumococcal Conjugate Vaccine work?
Who makes 20-valent Pneumococcal Conjugate Vaccine?
What is the generic name of 20-valent Pneumococcal Conjugate Vaccine?
What drug class is 20-valent Pneumococcal Conjugate Vaccine in?
What development phase is 20-valent Pneumococcal Conjugate Vaccine in?
Related
- Drug class: All Injection in the muscle or subcutaneous , 1 dose 0.5mL drugs
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing